BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 118 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2015. The put-call ratio across all filers is 0.63 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $4,379,730 | +45.4% | 618,606 | +44.6% | 0.00% | 0.0% |
Q2 2023 | $3,011,572 | +31.5% | 427,780 | +55.8% | 0.00% | 0.0% |
Q1 2023 | $2,289,539 | -32.4% | 274,525 | -6.9% | 0.00% | -50.0% |
Q4 2022 | $3,385,934 | +295.6% | 294,942 | +334.1% | 0.00% | – |
Q3 2022 | $856,000 | -51.4% | 67,939 | -59.2% | 0.00% | -100.0% |
Q2 2022 | $1,762,000 | -89.9% | 166,558 | -84.5% | 0.00% | -83.3% |
Q1 2022 | $17,473,000 | +21.0% | 1,074,635 | +3.0% | 0.01% | +50.0% |
Q4 2021 | $14,446,000 | -21.2% | 1,043,018 | -18.3% | 0.00% | -33.3% |
Q3 2021 | $18,343,000 | -7.1% | 1,276,481 | +2.2% | 0.01% | -25.0% |
Q2 2021 | $19,749,000 | +43.3% | 1,249,076 | -7.8% | 0.01% | +14.3% |
Q1 2021 | $13,785,000 | +175.4% | 1,355,373 | +101.7% | 0.01% | +250.0% |
Q4 2020 | $5,005,000 | +391.7% | 671,860 | +126.7% | 0.00% | – |
Q3 2020 | $1,018,000 | -30.6% | 296,328 | -3.7% | 0.00% | -100.0% |
Q2 2020 | $1,466,000 | +1443.2% | 307,611 | +544.7% | 0.00% | – |
Q1 2020 | $95,000 | +69.6% | 47,714 | +191.5% | 0.00% | – |
Q4 2019 | $56,000 | +16.7% | 16,370 | -2.2% | 0.00% | – |
Q3 2019 | $48,000 | -30.4% | 16,730 | -8.4% | 0.00% | – |
Q2 2019 | $69,000 | -48.9% | 18,271 | -33.7% | 0.00% | – |
Q4 2017 | $135,000 | -71.6% | 27,549 | -67.9% | 0.00% | -100.0% |
Q2 2017 | $476,000 | +336.7% | 85,700 | +559.2% | 0.00% | – |
Q1 2017 | $109,000 | +60.3% | 13,000 | +21.5% | 0.00% | – |
Q4 2016 | $68,000 | -27.7% | 10,700 | -67.9% | 0.00% | -100.0% |
Q1 2016 | $94,000 | -48.1% | 33,348 | +90.2% | 0.00% | 0.0% |
Q4 2015 | $181,000 | -7.2% | 17,537 | +2.6% | 0.00% | 0.0% |
Q3 2015 | $195,000 | +16.8% | 17,100 | -0.1% | 0.00% | -50.0% |
Q3 2014 | $167,000 | -87.7% | 17,114 | -84.0% | 0.00% | -88.2% |
Q2 2014 | $1,361,000 | -28.7% | 106,801 | -40.8% | 0.02% | -19.0% |
Q1 2014 | $1,909,000 | – | 180,460 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sarissa Capital Management LP | 3,926,700 | $56,427,000 | 4.43% |
ORACLE INVESTMENT MANAGEMENT INC | 1,920,733 | $27,601,000 | 3.44% |
HealthCor Management, L.P. | 3,849,470 | $55,317,000 | 2.39% |
MPM BioImpact LLC | 704,767 | $10,128,000 | 1.57% |
Baker Brothers Advisors | 12,710,818 | $182,654,000 | 0.80% |
Bain Capital Public Equity Management II, LLC | 1,472,471 | $21,159,000 | 0.74% |
Biondo Investment Advisors, LLC | 267,480 | $3,844,000 | 0.66% |
North Star Investment Management Corp. | 442,900 | $6,364,000 | 0.52% |
DOLIVER ADVISORS, LP | 100,000 | $1,437,000 | 0.48% |
Lisanti Capital Growth, LLC | 219,450 | $3,153,000 | 0.46% |